Set, Setting, Forgetting: Silence on Abuse in Psychedelic Therapy Histories
Mad in America
DECEMBER 18, 2024
Psychedelic therapy advocates consistently dismiss these concerns as exaggerated or isolated incidents that are inevitable in any therapy. The case most relevant to the MAPS FDA application started around 2015 at a Phase II trial site in Canada. A very different picture emerges. Ingrasci continues to use ‘M.D.
114 
Let's personalize your content